Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus
Key facts
- Who runs it
- Centre of Postgraduate Medical Education
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 62 people enrolled
- Started
- 1 Dec 2021
- Ended
- 5 May 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Endoscopic radiofrequency ablation
- Endoscopic hybrid argon plasma coagulation
- Record updated
- 3 October 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female subjects over 18 years
- Histologically and endoscopically proven Barrett's esophagus requiring ablation therapy according to the current guidelines
- General health status sufficient to perform an endoscopic procedure (ASA I-III)
Who cannot take part
- Recent myocardial infraction or other significant cardiovascular event within 6 months prior to recruitment
- Anticoagulation therapy (e.g. warfarin) for high-risk condition and unable to withhold the medication temporarily
- Patients under long-term care and/or within nursing facilities (e.g. psychosocial disorders, mental retardation)
- Any history of esophageal resection surgery
- Primary or secondary coagulopathy, with INR>1.5 and/or platelet count of <75,000
- Esophageal varices
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study compares patients' acceptability and safety of two established endoscopic methods for treating dysplastic Barrett's esophagus: radiofrequency ablation versus hybrid argon plasma coagulation.
The 2 groups in the trial
- radiofrequency ablationExisting treatment, for comparison
Circumferential ablation with radiofrequency ablation will be performed for each segment of the BE starting from the proximal end with one ablation at 12J/cm2, followed by cleaning of mucosal slough with esophageal cap, patient extubation, cleaning of ablation device with wet gauze, and finally a second ablation at 12 J/cm2 (1 × 12J/cm2-clean-1 × 12 J/cm2). Focal ablations will be performed with three consecutive ablations at 12 J/cm2 without cleaning (simplified protocol).
Treatment: Endoscopic radiofrequency ablation
- hybrid argon plasma coagulationExisting treatment, for comparison
Patients in the Hybrid argon plasma coagulation group will be treated with a single ablation per session with a power limitation of 60 W (pulsed mode (VIO® 300 D \& APC 2, PULSED APC®, Effect 2). No scraping with the endoscope cap and second ablation will be performed.
Treatment: Endoscopic hybrid argon plasma coagulation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus - the Patients' Perspective: a Randomized Controlled Trial Assessing Procedural Acceptability and Safety (RATE Study)
- Record updated
- 3 October 2025